Log in to save to my catalogue

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patter...

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patter...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b66ddf1ad30c445e87c57bf515f577a5

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

About this item

Full title

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

Publisher

London: Nature Publishing Group UK

Journal title

Blood cancer journal (New York), 2023-01, Vol.13 (1), p.19-19, Article 19

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in new treatments in recent years, yet real-world data on the management of the disease are scarce. EMN23 is a retrospective, observational study of patients who initiated first-line treatment in 2004–2018 in Europe, presenting the demographics, clinic...

Alternative Titles

Full title

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_b66ddf1ad30c445e87c57bf515f577a5

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b66ddf1ad30c445e87c57bf515f577a5

Other Identifiers

ISSN

2044-5385

E-ISSN

2044-5385

DOI

10.1038/s41408-023-00789-8

How to access this item